Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


11.09.2017

2 Acta Haematol
4 Blood
1 BMC Cancer
1 Bone Marrow Transplant
10 Br J Haematol
1 Cancer
1 Cancer Lett
2 J Pediatr Hematol Oncol
3 Leuk Lymphoma
4 Leuk Res
7 Leukemia
1 Oncogene
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Haematol

  1. LEADER A, Raanani P
    Switching-On Adherence in Chronic Myeloid Leukemia.
    Acta Haematol. 2017;138:138-139.
    PubMed     Text format    

  2. MAEDA Y, Okamoto A, Kawaguchi SI, Konishi A, et al
    Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors.
    Acta Haematol. 2017;138:140-142.
    PubMed     Text format    


    Blood

  3. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available

  4. BARR PM, Brown JR, Hillmen P, O'Brien S, et al
    Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Blood. 2017;129:2612-2615.
    PubMed     Text format     Abstract available

  5. VALGARDSDOTTIR R, Cattaneo I, Klein C, Introna M, et al
    Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
    Blood. 2017;129:2636-2644.
    PubMed     Text format     Abstract available

  6. LIYANAGE SU, Hurren R, Voisin V, Bridon G, et al
    Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
    Blood. 2017;129:2657-2666.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. REIKVAM H, Hovland R, Forthun RB, Erdal S, et al
    Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
    BMC Cancer. 2017;17:630.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  8. KORDELAS L, Buttkereit U, Lindemann M, Koldehoff M, et al
    alphabeta-T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Sep 4. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    Br J Haematol

  9. STRATI P, Parikh SA, Chaffee KG, Achenbach SJ, et al
    CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2017;178:99-105.
    PubMed     Text format     Abstract available

  10. JONES JA, Hillmen P, Coutre S, Tam C, et al
    Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    Br J Haematol. 2017;178:286-291.
    PubMed     Text format     Abstract available

  11. SOARES M, Saussoy P, Maskens M, Reul H, et al
    Eliminating malignant cells from cryopreserved ovarian tissue is possible in leukaemia patients.
    Br J Haematol. 2017;178:231-239.
    PubMed     Text format     Abstract available

  12. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Text format     Abstract available

  13. THEUNISSEN PMJ, Sedek L, De Haas V, Szczepanski T, et al
    Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Br J Haematol. 2017;178:257-266.
    PubMed     Text format     Abstract available

  14. MARTINI V, Gattazzo C, Frezzato F, Trimarco V, et al
    Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
    Br J Haematol. 2017;178:81-93.
    PubMed     Text format     Abstract available

  15. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2017;178:106-111.
    PubMed     Text format     Abstract available

  16. WILLIAMS J, Heppel NH, Britt-Compton B, Grimstead JW, et al
    Telomere length is an independent prognostic marker in MDS but not in de novo AML.
    Br J Haematol. 2017;178:240-249.
    PubMed     Text format     Abstract available

  17. THEUNISSEN PMJ, van den Branden A, Van Der Sluijs-Gelling A, De Haas V, et al
    Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2017;178:267-278.
    PubMed     Text format     Abstract available

  18. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Text format     Abstract available


    Cancer

  19. BUCKLEY SA, Jimenez-Sahagun D, Othus M, Walter RB, et al
    Quality of life from the perspective of the patient with acute myeloid leukemia.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30982.
    PubMed     Text format     Abstract available


    Cancer Lett

  20. SADRAS T, Heatley SL, Kok CH, Dang P, et al
    Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
    Cancer Lett. 2017 Sep 1. pii: S0304-3835(17)30521.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  21. FOSTER JH, Bernhardt MB, Thompson PA, Smith EO, et al
    Using a Bedside Algorithm to Individually Dose High-dose Methotrexate for Patients at Risk for Toxicity.
    J Pediatr Hematol Oncol. 2017;39:72-76.
    PubMed     Text format     Abstract available

  22. GRIMES A, Mirkheshti N, Chatterjee B, Tomlinson G, et al
    Paraneoplastic Galactorrhea in Childhood T-ALL: An Evaluation of Tumor-derived Prolactin.
    J Pediatr Hematol Oncol. 2017;39:e18-e20.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  23. PALLAVAJJALA A, Kim D, Li T, Ghiaur G, et al
    Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-8. doi: 10.1080/10428194.2017.1372577.
    PubMed     Text format     Abstract available

  24. SHUKLA A, Shukla V, Joshi SS
    Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-9. doi: 10.1080/10428194.2017.1370548.
    PubMed     Text format     Abstract available

  25. RODRIGUEZ CM, Stanganelli C, Bussi C, Arroyo D, et al
    Intracytoplasmic filamentous inclusions and IGHV rearrangements in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 3:1-5. doi: 10.1080/10428194.2017.1370549.
    PubMed     Text format    


    Leuk Res

  26. SAKIHAMA S, Saito M, Kuba-Miyara M, Tomoyose T, et al
    Human T-cell leukemia virus type I Tax genotype analysis in Okinawa, the southernmost and remotest islands of Japan: Different distributions compared with mainland Japan and the potential value for the prognosis of aggressive adult T-cell leukemia/lym
    Leuk Res. 2017;61:18-24.
    PubMed     Text format     Abstract available

  27. NORSWORTHY KJ, DeZern AE, Tsai HL, Hand WA, et al
    Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.
    Leuk Res. 2017;61:25-32.
    PubMed     Text format     Abstract available

  28. YOUNESIAN S, Shahkarami S, Ghaffari P, Alizadeh S, et al
    DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
    Leuk Res. 2017;61:33-38.
    PubMed     Text format     Abstract available

  29. CHEN Y, Pourabdollah M, Atenafu EG, Tierens A, et al
    Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.
    Leuk Res. 2017;61:39-43.
    PubMed     Text format     Abstract available


    Leukemia

  30. BURNETT AK, Russell NH, Hills RK, Kell J, et al
    A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Leukemia. 2017;31:310-317.
    PubMed     Text format     Abstract available

  31. STENGEL A, Kern W, Haferlach T, Meggendorfer M, et al
    The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Leukemia. 2017;31:705-711.
    PubMed     Text format     Abstract available

  32. STRUSKI S, Lagarde S, Bories P, Puiseux C, et al
    NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Leukemia. 2017;31:565-572.
    PubMed     Text format     Abstract available

  33. MEDEIROS BC, Fathi AT, DiNardo CD, Pollyea DA, et al
    Isocitrate dehydrogenase mutations in myeloid malignancies.
    Leukemia. 2017;31:272-281.
    PubMed     Text format     Abstract available

  34. QAZILBASH MH, Wieder E, Thall PF, Wang X, et al
    PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
    Leukemia. 2017;31:697-704.
    PubMed     Text format     Abstract available

  35. SAENZ DT, Fiskus W, Manshouri T, Rajapakshe K, et al
    BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Leukemia. 2017;31:678-687.
    PubMed     Text format     Abstract available

  36. MARNETH AE, Prange KHM, Al Hinai ASA, Bergevoet SM, et al
    C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
    Leukemia. 2017 Sep 5. doi: 10.1038/leu.2017.
    PubMed     Text format     Abstract available


    Oncogene

  37. BURGESS M, Mapp S, Mazzieri R, Cheung C, et al
    Increased FcgammaRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients.
    Oncogene. 2017;36:2366-2376.
    PubMed     Text format     Abstract available


    PLoS One

  38. ALSOUS M, Abu Farha R, Alefishat E, Al Omar S, et al
    Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia.
    PLoS One. 2017;12:e0183119.
    PubMed     Text format     Abstract available

  39. BRODSKA B, Kracmarova M, Holoubek A, Kuzelova K, et al
    Localization of AML-related nucleophosmin mutant depends on its subtype and is highly affected by its interaction with wild-type NPM.
    PLoS One. 2017;12:e0175175.
    PubMed     Text format     Abstract available

  40. BANJAR H, Ranasinghe D, Brown F, Adelson D, et al
    Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia.
    PLoS One. 2017;12:e0168947.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: